Animals Dietary Supplements Humans Nitroso Compounds/*administration & dosage Risk Factors Urinary Bladder Neoplasms/*diagnosis Bladder Dietary Neoplasms Nitrate Nitrite Nitrosamines Organic chemicals

*Carcinoma Transitional Cell/drug therapy Female Humans Immune Checkpoint Inhibitors/therapeutic use Immunotherapy *Lung Neoplasms/pathology Male Platinum/therapeutic use Programmed Cell Death 1 Receptor *Urinary Bladder Neoplasms/drug therapy

Carcinoma Transitional Cell/*pathology/*surgery Humans Kidney Neoplasms/*pathology Neoplasms Second Primary/*pathology Nephrotomy Risk Factors Stents/*adverse effects Ureteral Obstruction/etiology/*surgery Urinary Bladder Neoplasms/*pathology/*surgery carcinoma transitional cell hydronephrosis meta-analysis stents urinary bladder neoplasms

Biomarkers Humans Inflammation Prognosis Proportional Hazards Models *Urinary Bladder Neoplasms bladder cancer meta-analysis survival systemic immune-inflammation index commercial or financial relationships that could be construed as a potential conflict of interest.

Bladder cancer Cytology Hematuria Mcm5 Urinary markers to the content of this report.

*Carcinoma Transitional Cell Case-Control Studies Epidemiologic Studies Female Folic Acid Humans Male Prospective Studies Risk Factors *Urinary Bladder Neoplasms/epidemiology/etiology/prevention & control

*Cystectomy/adverse effects Humans Postoperative Complications/epidemiology/etiology Prospective Studies Retrospective Studies *Robotic Surgical Procedures/adverse effects *Robotics Treatment Outcome *Urinary Bladder Neoplasms/surgery Bladder cancer Intracorporeal Meta-analysis Radical cystectomy Robot-assisted

Cystectomy/adverse effects Female Humans Male Network Meta-Analysis *Urinary Bladder Neoplasms/pathology/surgery Urologic Surgical Procedures Tueb Turbt bladder cancer en bloc transurethral en bloc transurethral resection

*Cystectomy Humans Prospective Studies Systematic Reviews as Topic Treatment Outcome Urinary Bladder/pathology/surgery *Urinary Bladder Neoplasms/pathology/surgery models mortality nomograms radical cystectomy urinary bladder neoplasms

Apoptosis B7-H1 Antigen/genetics/metabolism *Carcinoma Transitional Cell/pathology Cystectomy Humans Immune Checkpoint Inhibitors Ligands Lymph Node Excision Neoplasm Recurrence Local/pathology Prognosis Programmed Cell Death 1 Receptor Urinary Bladder *Urinary Bladder Neoplasms/pathology bladder urothelial carcinoma meta-analysis prognostic value programmed cell death ligand-1 radical cystectomy commercial or financial relationships that could be construed as a potential conflict of interest.

Humans *Carcinoma Transitional Cell/diagnosis/therapy *Urinary Bladder Neoplasms Systematic Reviews as Topic Kidney Oregon *Ureteral Neoplasms/diagnosis/therapy Utuc renal pelvis cancer upper tract urothelial cancer ureteral cancer urothelial cancer

bladder cancer cohort cruciferous vegetables meta-analysis risk commercial or financial relationships that could be construed as a potential conflict of interest.

Antineoplastic Combined Chemotherapy Protocols/therapeutic use *Carcinoma Transitional Cell/pathology Cisplatin/therapeutic use Cystectomy Humans Muscles/pathology Neoadjuvant Therapy Neoplasm Invasiveness *Urinary Bladder Neoplasms/pathology Bladder cancer Muscle-invasive Urothelial from MSD and BMS and Speaker and Other from AstraZecena. BPV reports Advisory Board Speaker and Other from Astellas Roche BMS and Merk-Pfizer Advisory Board and Other from Ipsen Advisory Board and Speaker from EUSA and MSD and Advisory Board from Sanofi. IPF report Advisory Board Speaker and Other from Pfizer Speaker and Other from Ipsen and Roche Advisory Board from EUSA and BMS and Speaker from Novartis and MSD. OFC reports Advisory Board and Speaker from Ipsen and Astellas Advisory Board from BMS and Pfizer-Merck and Speaker from AstraZeneca. AGA has received research funding from Astellas travel grants from Astellas Jansen Sanofi BMS Roche Pfizer and Ipsen and honoraria for speaker engagements advisory boards and continuous medical education from Janssen Astellas Sanofi Bayer Roche Ipsen BMS MSD Pfizer Eusa Pharma Eisai and AstraZeneca. JAA reports honoraria from Astellas Pfizer and BMS conulting or advisory role from Pfizer Astellas Janssen-Cilag MSD Oncology BMS Merck AstraZeneca Bayer and Eisai and Research Funding from BMS. RMB SVE CCD and MDS have nothing to disclose.

Cystectomy France Humans Lymphatic Irradiation Palliative Care Patient Positioning Radiation Oncology Radiotherapy Dosage Radiotherapy Adjuvant Radiotherapy Conformal Urinary Bladder Neoplasms/diagnostic imaging/pathology/*radiotherapy/surgery Bladder cancer Cancers de la vessie Chemoradiation Chimioradiothérapie French society for radiation oncology Guidelines Radiation therapy Radiothérapie Recommandations Société française de radiothérapie oncologique

Autoantigens Biomarkers Tumor/genetics/metabolism Gene Expression Regulation Neoplastic Humans Procollagen-Lysine 2-Oxoglutarate 5-Dioxygenase/genetics/metabolism Prognosis *Urinary Bladder Neoplasms/pathology Bladder cancer Meta-analysis Microarray datasets Overall survival Prognostic biomarker

Cystectomy/*methods Humans *Margins of Excision Survival Rate Ureter/*surgery Urinary Bladder Neoplasms/mortality/*surgery Bladder cancer Cancer de vessie Cystectomie Cystectomy Examen extemporané Frozen section Recoupes urétérales Ureteral margin

Radical cystectomy bladder preservation distant metastasis rate (DMR) muscular invasive bladder cancer (MIBC) survival rate form (available at https://dx.doi.org/10.21037/tau-21-564). The authors have no conflicts of interest to declare.

Aminolevulinic Acid China Cystoscopy Humans Neoplasm Recurrence Local *Photochemotherapy/methods Photosensitizing Agents *Urinary Bladder Neoplasms/diagnosis 5-aminolevulinic acid Bladder cancer Fluorescent cystoscopy Hexylaminolevulinate

Humans Biomarkers Tumor *Carcinoma in Situ/diagnosis *Carcinoma Transitional Cell/pathology Hyaluronan Receptors/metabolism Keratin-20/analysis/metabolism Ki-67 Antigen/metabolism Tumor Suppressor Protein p53/analysis/metabolism Urinary Bladder *Urinary Bladder Neoplasms/pathology Urothelium/chemistry/metabolism/pathology Bladder carcinoma Carcinoma in situ Carcinoma vesical Displasia Dysplasia Immunomarkes Inmunomarcadores

Antineoplastic Combined Chemotherapy Protocols/adverse effects Bayes Theorem *Carcinoma Transitional Cell/drug therapy/surgery Humans Network Meta-Analysis *Urinary Bladder Neoplasms/drug therapy/surgery Ici Pd-1 Pd-l1 adjuvant therapy chemotherapy urothelial carcinoma